المؤلفون: T. Deshkina I., L. Bolotina V., A. Gevorkov R., A. Boyko V., V. Surkova S., M. Sedova V., A. Polyakov P., A. Kornietskaya L., A. Fedenko A., Т. Дешкина И., Л. Болотина В., А. Геворков Р., А. Бойко В., В. Суркова С., М. Седова В., А. Поляков П., А. Корниецкая Л., А. Феденко А.

المصدر: Head and Neck Tumors (HNT); Том 11, № 4 (2021); 110-118 ; Опухоли головы и шеи; Том 11, № 4 (2021); 110-118 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2017-0-4

مصطلحات موضوعية: neuroendocrine cancer, sinonasal carcinoma, maxillary sinus cancer, нейроэндокринный рак, синоназальная карцинома, рак верхнечелюстной пазухи

وصف الملف: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/723/509; Thompson L.D.R. Sinonasal carcinomas. Current Diagnostic Pathol 2006;12:40–53. DOI:10.1016/j.cdip.2005.10.009.; Shah J., Patel S., Singh B., Wong R. Head and neck surgery and oncology. 5 th ed. Elsevier Mosby, 2020. 896 p. DOI:10.3342/kjorl-hns.2012.55.12.805.; Head and neck cancer. Multimodality management. 2 nd ed. Ed. by J. Bernier. Springer International Publishing Switzerland, 2016. 859 p. DOI:10.1007/978-3-319-27601-4.; Hansen E.K., Roach M. Handbook of evidence-based radiation oncology. 3 rd ed. Springer International Publishing AG, 2018. 926 p. DOI:10.1007/978-3-319-62642-0.; Van der Laan T.P., Iepsma R., Witjes M.J.H. et al. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol 2016;63:1–9. DOI:10.1016/j.oraloncology.2016.10.002.; Rosenthal D.I., Barker J.L.Jr., El-Naggar A.K. et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004;101(11):2567–73. DOI:10.1002/cncr.20693.; Raychowdhuri R.N. Oat-cell carcinoma and paranasal sinuses. J Laryngol Otol 1965;79(3):253–5. DOI:10.1017/S0022215100063660.; Silva E.G., Butler J.J., MacKay B., Goepfert H. Neuroblastomas and neuroendocrine carcinomas of the nasal cavity. A proposed new classification. Cancer 1982;50(11):2388–405. DOI:10.1002/1097-0142(19821201)50:113.0.co;2-k.; Thompson L. Pathology and genetics head and neck. Ear Nose Throat J 2006;85(2):74.; Renner G. Small cell carcinoma of the head and neck: a review. Semin Oncol 2007;34(1):3–14. DOI:10.1053/j.seminoncol2006.10.024.; Fitzek M.M., Thornton A.F., Varvares M. et al. Neuroendocrine tumors of the sinonasal tract: results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002;94(10):2623–34. DOI:10.1002/cncr.10537.; Bhattacharyya N., Thornton A.F., Joseph M.P. et al. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: results in 9 cases. Arch Otolaryngol 1997;123(1):34–40. DOI:10.1001/archotol.1997.01900010038005.; Babin E., Rouleau V., Vedrine P.O. et al. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol 2006;120(4):289–97. DOI:10.1017/S0022215106000594.; Likhacheva A., Rosenthal D.I., Hanna E. et al. Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol 2011;3:32. DOI:10.1186/1758-3284-3-32.; Chang C.F., Li W.Y., Shu C.H., Ho C.Y. Sino-nasal neuro-endocrine carcinoma. Acta Oto-Laryngologica 2010;130(3):392–7. DOI:10.1080/00016480903148274.; Qian G.H., Shang J.B., Wang K.J., Tan Z. Diagnosis and treatment of 11 cases with sinonasal neuroendocrine carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;46(12):1033–5. [In Chinese].; https://ogsh.abvpress.ru/jour/article/view/723

الاتاحة: https://ogsh.abvpress.ru/jour/article/view/723
https://doi.org/10.17650/2222-1468-2021-11-4-110-118

المؤلفون: M. Fedyanin Yu., H. Elsnukaeva H.‑M., I. Demidova A., D. Stroyakovskii L., Yu. Shelygin A., A. Tsukanov S., Yu. Sergeev S., A. Ponomarenko A., M. Panina V., V. Shubin P., F. Moiseenko V., E. Karpenko Yu., L. Bolotina V., A. Kudriavtseva V., M. Filipenko L., M. Voskoboev E., I. Oskorbin P., L. Vladimirova Yu., O. Kit I., A. Stroganova M., S. Dranko L., A. Senderovich I., A. Tryakin A., S. Tjulandin A., М. Федянин Ю., Х. Эльснукаева Х.‑М., И. Демидова А., Д. Строяковский Л., Ю. Шелыгин А., А. Цуканов С., Ю. Сергеев С., А. Пономаренко А., М. Панина В., В. Шубин П., Ф. Моисеенко В., Е. Карпенко Ю., Л. Болотина В., А. Кудрявцева В., М. Филипенко Л., М. Воскобоев Е., И. Оскорбин П., Л. Владимирова Ю., О. Кит И., А. Строганова М., С. Дранко Л., А. Сендерович И., А. Трякин А., С. Тюляндин А.

المصدر: Malignant tumours; Том 11, № 3 (2021); 5-14 ; Злокачественные опухоли; Том 11, № 3 (2021); 5-14 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: colon cancer, metastasectomy, BRAF gene mutation, рак толстой кишки, метастазэктомия, BRAF

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/915/661; Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer. 2018; 18: 78.; Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27 (22):3677-83. doi:10.1200/JCO. 2008.20.5278.; Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, Capussotti L, Lapointe R, Regimbeau JM, Lopez – Ben; S, Isoniemi H, Hubert C, Lin JK, Gruenberger T, Elias D, Skipenko OG, Guglielmi A, LiverMetSurvey International Contributing Centers. Resection of colorectal liver metastases afer second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017 Jun;78:7-15. doi:10.1016/j. ejca. 2017.03.009.; Spolverato G, Ejaz A, Azad N and Pawlik TM. Surgery for colorectal liver metastases: Te evolution of determining prognosis. World J Gastrointest Oncol. 2013 Dec 15; 5 (12): 207–221. doi:10.4251/wjgo.v5.i12.207.; Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M. Adjuvant therapy afer resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014;14:174. DOI: https://doi.org/10.1186/1471-2407-14-174.; de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009 Sep;250 (3):440-8. doi:10.1097/SLA. 0b013e3181b4539b.; Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal L F, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of fve randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016 Sep;27 (9):1746-53. doi:10.1093/annonc/mdw261. Epub 2016 Jun 29.; Chu JE, Johnson B, Morris VK, Raghav KPS, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Schaeffer DF, Kopetz S, Loree JM. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. Journal of Clinical Oncology. 2019;37, no. 15_suppl: 3579-3579. DOI:10.1200/JCO. 2019.37.15_suppl. 3579.; Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Taler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P, Pan-European Trials in Alimentary Tract Cancer (PETACC) -8 Investigators. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol. 2018 Jul 12;4 (7):e173695. doi:10.1001/jamaoncol. 2017.3695.; Renaud S, Romain B, Falcoz P-E, Olland A, Santelmo N, Brigand C, Rohr S, Guenot D, Massard G. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015 Feb 17;112 (4):720-8. doi:10.1038/bjc. 2014.499.; Hernández-Sandoval JA, Gutiérrez-Angulo M, Magaña-Torres MT, Alvizo-Rodríguez CR, Ramírez-Plascencia HHF, Flores-López BA, Valenzuela-Pérez JA, Peregrina-Sandoval J, Moreno-Ortiz JM, Domínguez-Valentín M, de la Luz Ayala-Madrigal M. Prevalence of the BRAF p. v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J Investig Med. 2020 Jun;68 (5):985-991. doi:10.1136/jim-2020-001301. Oncol Rep. https://doi.org/10.3892/or.2011.1217.; Morris VK, Kee BK, Overman MJ, Fogelman DR, Dasari A, Raghav KPS, Shureiqi I, Johnson B, Parseghian CM, Wolff RA, Eng C, Garg N, Kopetz S. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. J Clin Oncol 38: 2020 (suppl; abstr 4047). DOI:10.1200/JCO.2020.38.15_suppl.4047.; Ortega L, Beranek MB, Alonso NG, Alsar JS, Bianchi MA, Valles MA, Salcedo IA, Gallego IG, González GG, Pérez-Solero GT, Martín AJM, Ferrándiz AC, Blanco-Codesido M, Martin M, Garcia-Alfonso P. Metastases resection in colorectal cancer patients with mutation in oncogene BRAF or tumors located on the right side: Experience at the HGUGM. J Clin Oncol 38: 2020 (suppl; abstr 4041). DOI:10.1200/JCO. 020.38.15_suppl.4041.; Prasanna T, Wong R, Price T, Shapiro J, Tie J, Wong HL, Nott L, Roder D, Lee M, Kosmider S, Jalali A, Burge M, Padbury R, Maddern G, Carruthers S, Moore J, Sorich M, Karapetis CS, Gibbs P, Yip D. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Curr Probl Cancer. 2020 Aug 14;100637. doi:10.1016/j. currproblcancer. 2020.100637. Online ahead of print.; Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018 Jul 18;153 (7):e180996. doi:10.1001/jamasurg. 2018.0996.; Johnson B, Jin Z, Truty MJ, et al. Impact of metastasectomy in the multimodality approach for braf v600e metastatic colorectal cancer: the Mayo Clinic experience. Oncologist. 2018;23:128–134. doi:10.1634/theoncologist. 2017-0230.; Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921–1928. doi:10.1038/bjc. 2015.142.; Teng HW, Huang YC, Lin JK et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012;106:123–129.; Yaeger R, Cercek A, Chou JF et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014;120:2316–2324.; Larsen SG, Dueland S, Goscinski M, et al. Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peri-toneal metastases from colorectal cancer. J Clin Oncol. 2019;37 (15_suppl): 3565. doi:10.1200/JCO. 2019.37.15_suppl.3565.; Montañá JR, Martini G, Baraibar I, Villacampa G, Comas R, Ciardiello D, Garcia A, Yague XH, Queralt B, Salvia AS, Argiles G, Cuadra JL, Toledo RA, Chicote I, Mulet N, Vivancos A, Palmer HG, Dienstmann R, Tabernero J, Elez E. Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) meta-static colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. J Clin Oncol 38: 2020 (suppl; abstr 4112). DOI:10.1200/JCO.2020.38.15_suppl.4112.; https://www.malignanttumors.org/jour/article/view/915

الاتاحة: https://www.malignanttumors.org/jour/article/view/915
https://doi.org/10.18027/2224-5057-2021-11-3-5-14

المؤلفون: V. Potievskaya I., A. Akhobekov A., L. Bolotina V., L. Koroleva A., A. Kaprin D., В. Потиевская И., А. Ахобеков А., Л. Болотина В., Л. Королева А., А. Каприн Д.

المصدر: Siberian journal of oncology; Том 20, № 5 (2021); 138-148 ; Сибирский онкологический журнал; Том 20, № 5 (2021); 138-148 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-5

مصطلحات موضوعية: breast cancer, anticancer therapy, cardiotoxicity, cardiovascular disease, рак молочной железы, противоопухолевая терапия, кардиотоксичность, сердечно-сосудистые заболевания

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1927/912; Bradshaw P.T., Stevens J., Khankari N., Teitelbaum S.L., Neugut A.I., Gammon M.D. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology. 2016 Jan; 27(1): 6–13. doi:10.1097/EDE.0000000000000394.; Park N.J., Chang Y., Bender C., Conley Y., Chlebowski R.T., van Londen G.J., Foraker R., Wassertheil-Smoller S., Stefanick M.L., Kuller L.H. Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women’s Health Initiative. PLoS One. 2017 Sep 21; 12(9): e0184174. doi:10.1371/journal.pone.0184174.; Polk A., Shahmarvand N., Vistisen K., Vaage-Nilsen M., Larsen F.O., Schou M., Nielsen D.L. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open. 2016 Oct 19; 6(10): e012798. doi:10.1136/bmjopen-2016-012798.; National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Female Breast Cancer [Internet]. URL: https://seer.cancer.gov/statfacts/html/breast.html (cited 9.10.2018).; Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov; 18(11): 1639–42. doi:10.1038/nm.2919.; Narayan H.K., Finkelman B., French B., Plappert T., Hyman D., Smith A.M., Margulies K.B., Ky B. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation. 2017 Apr 11; 135(15): 1397–1412. doi:10.1161/CIRCULATIONAHA.116.023463.; Kotamraju S., Chitambar C.R., Kalivendi S.V., Joseph J., Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidantinduced iron signaling in apoptosis. J Biol Chem. 2002 May 10; 277(19): 17179–87. doi:10.1074/jbc.M111604200.; Kersting G., Tzvetkov M.V., Huse K., Kulle B., Hafner V., Brockmöller J., Wojnowski L. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(1): 21–30. doi:10.1007/s00210-006-0091-0.; Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1; 97(11): 2869–79. doi:10.1002/cncr.11407.; Mackey J.R., Martin M., Pienkowski T., Rolski J., Guastalla J.P., Sami A., Glaspy J., Juhos E., Wardley A., Fornander T., Hainsworth J., Coleman R., Modiano M.R., Vinholes J., Pinter T., Rodríguez-Lescure A., Colwell B., Whitlock P., Provencher L., Laing K., Walde D., Price C., Hugh J.C., Childs B.H., Bassi K., Lindsay M.A., Wilson V., Rupin M., Houé V., Vogel C.; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1): 72–80. doi:10.1016/S1470-2045(12)70525-9.; Bonneterre J., Roché H., Kerbrat P., Fumoleau P., Goudier M.J., Fargeot P., Montcuquet P., Clavère P., Barats J.C., Monnier A., Veyret C., Datchary J., Van Praagh I., Chapelle-Marcillac I. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol. 2004 Aug 1; 22(15): 3070–9. doi:10.1200/JCO.2004.03.098.; Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25(25): 3808–15. doi:10.1200/JCO.2006.10.4976.; Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep 2; 64(9): 938–45. doi:10.1016/j.jacc.2014.06.1167.; Marty M., Espié M., Llombart A., Monnier A., Rapoport B.L., Stahalova V.; Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracyclinebased chemotherapy. Ann Oncol. 2006 Apr; 17(4): 614–22. doi:10.1093/annonc/mdj134.; Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997 Apr; 15(4): 1318–32. doi:10.1200/JCO.1997.15.4.1318.; Venturini M., Michelotti A., Del Mastro L., Gallo L., Carnino F., Garrone O., Tibaldi C., Molea N., Bellina R.C., Pronzato P., Cyrus P., Vinke J., Testore F., Guelfi M., Lionetto R., Bruzzi P., Conte P.F., Rosso R. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996; 14(12): 3112–20. doi:10.1200/JCO.1996.14.12.3112.; Lopez M., Vici P., Di Lauro K., Conti F., Paoletti G., Ferraironi A., Sciuto R., Giannarelli D., Maini C.L. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998; 16(1): 86–92. doi:10.1200/JCO.1998.16.1.86.; HERCEPTIN (trastuzumab). Highlights of Prescribing Information, Genentech, Inc., San Francisco, CA, October 2010. [Internet] URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf (9.10.2018).; Florido R., Smith K.L., Cuomo K.K., Russell S.D. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc. 2017 Sep 22; 6(9): e006915. doi:10.1161/JAHA.117.006915.; Onitilo A.A., Engel J.M., Stankowski R.V. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014; 5(4): 154–66. doi:10.1177/2042098614529603.; Yu A.F., Yadav N.U., Manrique C.R., Thaler H.T., Hudis C.A., Dang C.T., Steingart R.M. Impact of trastuzumab-induced cardiotoxicity and subsequent trastuzumab interruption on breast cancer outcome. Circulation. 2013; 128: A9317.; Lynce F., Barac A., Geng X., Dang C., Yu A.F., Smith K.L., Gallagher C., Pohlmann P.R., Nunes R., Herbolsheimer P., Warren R., Srichai M.B., Hofmeyer M., Cunningham A., Timothee P., Asch F.M., Shajahan-Haq A., Tan M.T., Isaacs C., Swain S.M. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2- positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019 Jun; 175(3): 595–603. doi:10.1007/s10549-019-05191-2.; Mantarro S., Rossi M., Bonifazi M., D'Amico R., Blandizzi C., La Vecchia C., Negri E., Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016 Feb; 11(1): 123–40. doi:10.1007/s11739-015-1362-x.; Ky B., Putt M., Sawaya H., French B., Januzzi J.L.Jr., Sebag I.A., Plana J.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., Gerszten R.E., Halpern E.F., Passeri J., Kuter I., ScherrerCrosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4; 63(8): 809–16. doi:10.1016/j.jacc.2013.10.061.; Mohan N., Jiang J., Dokmanovic M., Wu W.J. Trastuzumabmediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018 Aug 31; 1(1): 13–17. doi:10.1093/abt/tby003.; Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21; 37(36): 2768–2801. doi:10.1093/eurheartj/ehw211.; Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C.M. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan; 55(3): 213–20. doi:10.1016/j.jacc.2009.03.095.; Earl H.M., Hiller L., Vallier A.L., Loi S., Howe D., Higgins H.B., PERSEPHONE Trial Investigators. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 2018; 36(15): 506.; Sendur M.A., Aksoy S., Altundag K. Cardiotoxicity of novel HER2- targeted therapies. Curr Med Res Opin. 2013 Aug; 29(8): 1015–24. doi:10.1185/03007995.2013.807232.; SABCS 2019 [Internet]. URL: https://www.practiceupdate.com/content/sabcs-2019-recommendations-from-dr-sara-tolaney/93466 (cited 23.02.2020).; Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000 Apr; 22(4): 263–302. doi:10.2165/00002018-200022040-00002.; Khosrow-Khavar F., Filion K.B., Al-Qurashi S., Torabi N., Bouganim N., Suissa S., Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1; 28(3): 487–496. doi:10.1093/annonc/mdw673.; Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., André F., Harbeck N., Aguilar Lopez B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortés J., Curigliano G., Diéras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L., Winer E.P. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018; 29(8): 1634–57. doi:10.1093/annonc/mdy192.; Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A., Petrakova K., Bianchi G.V., Esteva F.J., Martín M., Nusch A., Sonke G.S., De la Cruz-Merino L., Beck J.T., Pivot X., Vidam G., Wang Y., Rodriguez Lorenc K., Miller M., Taran T., Jerusalem G. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24): 2465 2472. doi:10.1200/JCO.2018.78.9909.; Lilly’s Verzenio® (abemaciclib) significantly extended life in women with HR+, HER2- advanced breast cancer in MONARCH-2. July 30, 2019 [Internet]. URL: https://investor.lilly.com/news-releases/news-release-details/lillys-verzenior-abemaciclib-significantly-extendedlife-women (cited 23.02.2020).; Sledge G.W.Jr., Toi M., Neven P., Sohn J., Inoue K., Pivot X., Burdaeva O., Okera M., Masuda N., Kaufman P.A., Koh H., Grischke E.M., Frenzel M., Lin Y., Barriga S., Smith I.C., Bourayou N., Llombart-Cussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017 Sep 1; 35(25): 2875– 2884. doi:10.1200/JCO.2017.73.7585.; Tripathy D., Im S.A., Colleoni M., Franke F., Bardia A., Harbeck N., Hurvitz S.A., Chow L., Sohn J., Lee K.S., Campos-Gomez S., Villanueva Vazquez R., Jung K.H., Babu K.G., Wheatley-Price P., De Laurentiis M., Im Y.H., Kuemmel S., El-Saghir N., Liu M.C., Carlson G., Hughes G., DiazPadilla I., Germa C., Hirawat S., Lu Y.S. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul; 19(7): 904–915. doi:10.1016/S1470-2045(18)30292-4.; Im S.A., Lu Y.S., Bardia A., Harbeck N., Colleoni M., Franke F., Chow L., Sohn J., Lee K.S., Campos-Gomez S., Villanueva-Vazquez R., Jung K.H., Chakravartty A., Hughes G., Gounaris I., Rodriguez-Lorenc K., Taran T., Hurvitz S., Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25; 381(4): 307–316. doi:10.1056/NEJMoa1903765.; Министерство здравоохранения Российской Федерации. Инструкция по медицинскому применению лекарственного препарата РИСАРГ ЛП-004670. 30 c.; Durairaj C., Ruiz-Garcia A., Gauthier E.R., Huang X., Lu D.R., Hoffman J.T., Finn R.S., Joy A.A., Ettl J., Rugo H.S., Zheng J., Wilner K.D., Wang D.D. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 Mar; 29(3): 271–280. doi:10.1097/CAD.0000000000000589.; Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977–82. doi:10.1161/01.CIR.0000085166.44904.79.; SOLVD Investigators, Yusuf S., Pitt B., Davis C.E., Hood W.B.Jr., Cohn J.N. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep 3; 327(10): 685–91. doi:10.1056/NEJM199209033271003.; Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349(20): 1893–906. doi:10.1056/NEJMoa032292.; Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E.Jr., Colvin M.M., Drazner M.H., Filippatos G.S., Fonarow G.C., Givertz M.M., Hollenberg S.M., Lindenfeld J., Masoudi F.A., McBride P.E., Peterson P.N., Stevenson L.W., Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8; 136(6): e137–e161. doi:10.1161/CIR.0000000000000509.; Lipshultz S.E., Lipsitz S.R., Sallan S.E., Simbre V.C.2nd, Shaikh S.L., Mone S.M., Gelber R.D., Colan S.D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 1; 20(23): 4517–22. doi:10.1200/JCO.2002.12.102.; Herrmann J., Lerman A., Sandhu N.P., Villarraga H.R., Mulvagh S.L., Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep; 89(9): 1287–306. doi:10.1016/j.mayocp.2014.05.013.; Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., Civelli M., Peccatori F., Martinelli G., Fiorentini C., Cipolla C.M. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8; 109(22): 2749–54. doi:10.1161/01.CIR.0000130926.51766.CC.; Ledwidge M., Gallagher J., Conlon C., Tallon E., O'Connell E., Dawkins I., Watson C., O'Hanlon R., Bermingham M., Patle A., Badabhagni M.R., Murtagh G., Voon V., Tilson L., Barry M., McDonald L., Maurer B., McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013 Jul 3; 310(1): 66–74. doi:10.1001/jama.2013.7588.; Armenian S.H., Lacchetti C., Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 Apr; 13(4): 270–275. doi:10.1200/JOP.2016.018770.; Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014 Jul 1; 63(25 Pt A): 2751–68. doi:10.1016/j.jacc.2014.01.073.; Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., Martinelli G., Veglia F., Fiorentini C., Cipolla C.M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec 5; 114(23): 2474–81. doi:10.1161/CIRCULATIONAHA.106.635144.; Gulati G., Heck S.L., Ree A.H., Hoffmann P., Schulz-Menger J., Fagerland M.W., Gravdehaug B., von Knobelsdorff-Brenkenhoff F., Bratland Å., Storås T.H., Hagve T.A., Røsjø H., Steine .K, Geisler J., Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1; 37(21): 1671–80. doi:10.1093/eurheartj/ehw022.; Pituskin E., Mackey J.R., Koshman S., Jassal D., Pitz M., Haykowsky M.J., Pagano J.J., Chow K., Thompson R.B., Vos L.J., Ghosh S., Oudit G.Y., Ezekowitz J.A., Paterson D.I. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of TrastuzumabAssociated Cardiotoxicity. J Clin Oncol. 2017 Mar 10; 35(8): 870–877. doi:10.1200/JCO.2016.68.7830.; Seicean S., Seicean A., Plana J.C., Budd G.T., Marwick T.H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012; 60(23): 2384–90. doi:10.1016/j. jacc.2012.07.067.; Acar Z., Kale A., Turgut M., Demircan S., Durna K., Demir S., Meriç M., Ağaç M.T. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011 Aug 23; 58(9): 988–9. doi:10.1016/j.jacc.2011.05.025.; Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E.Jr., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., Johnson M.R., Kasper E.K., Levy W.C., Masoudi F.A., McBride P.E., Mc- Murray J.J., Mitchell J.E., Peterson P.N., Riegel B., Sam F., Stevenson L.W., Tang W.H., Tsai E.J., Wilkoff B.L.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15; 62(16): e147-239. doi:10.1016/j.jacc.2013.05.019.; Мацкеплишвили С.Т., Потиевская В.И., Поповкина О.Е., Болотина Л.В., Шкляева А.В., Полуэктова М.В., Каприн А.Д. Сердечнососудистые осложнения при лечении онкологических заболеваний (кардиоонкология): профилактика, диагностика, лечение – согласованное мнение экспертов. Технологии живых систем. 2018; 15(6): 3–35.; Плохова Е.В., Дундуа Д.П. Основные принципы профилактики и лечения кардиотоксичности на фоне химиотерапии у онкологических пациентов. Клиническая практика. 2019; 10(1): 31–41.; https://www.siboncoj.ru/jour/article/view/1927

الاتاحة: https://www.siboncoj.ru/jour/article/view/1927
https://doi.org/10.21294/1814-4861-2021-20-5-138-148

المؤلفون: E. Kovalenko I., E. Artamonova V., L. Bolotina V., L. Zhiliaeva A., D. Ponomarenko M., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., E. Ratner Yu., A. Safarova R., A. Manikhas G., N. Popova O., I. Evstigneeva V., L. Vladimirova Yu., L. Kramskaya V., T. Karandeeva V., I. Suslova R., O. Romanchuk V., V. Shikina E., A. Povyshev Yu., M. Osipov A., E. Cherniakova M., A. Dergunov S., M. Volkonskiy V., I. Chernov S., I. Shumskaya E., M. Fael M., V. Garifullina I., I. Gudkova E., Е. Коваленко И., Е. Артамонова В., Л. Болотина В., Л. Жиляева А., Д. Пономаренко М., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., Е. Ратнер Ю., А. Сафарова Р., А. Манихас Г., Н. Попова О., И. Евстигнеева В., Л. Владимирова Ю., Л. Крамская В., Т. Карандеева В., И. Суслова Р., О. Романчук В., В. Шикина Е., А. Повышев Ю., М. Осипов А., Е. Чернякова М., А. Дергунов С., М. Волконский В., И. Чернов С., И. Шумская Э., М. Фаель М., В. Гарифуллина И., И. Гудкова Е.

المساهمون: Данная публикация подготовлена при финансовой поддержке компании «Эйсай».

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 36-46 ; Медицинский Совет; № 20 (2021); 36-46 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: breast cancer, eribulin, trastuzumab, efficacy, tolerance, рак молочной железы, эрибулин, трастузумаб, эффективность, переносимость

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6578/5961; Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. https://doi.org/10.1126/science.3798106.; Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. https://doi.org/10.1056/NEJM200103153441101.; Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221. https://doi.org/10.1200/JCO.2002.20.5.1215.; Cortazar P., Justice R., Johnson J., Sridhara R., Keegan P., Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30(14):1705–1711. https://doi.org/10.1200/JCO.2011.39.2613.; Infante J.R., Yardley D.A., Burris H.A. 3rd, Greco F.A., Farley C.P., Webb C. et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer. 2009;9(1):23–28. https://doi.org/10.3816/CBC.2009.n.004.; Livingston R.B., Barlow W.E., Kash J.J., Albain K.S., Gralow J.R., Lew D.L. et al. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011;130(1):123–131. https://doi.org/10.1007/s10549-011-1698-5.; Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M. et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2- positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. https://doi.org/10.1056/NEJMoa1413513.; Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320.; Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. https://doi.org/10.1158/0008-5472.CAN-08-1776.; Barok M., Tanner M., Köninki K., Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46. https://doi.org/10.1186/bcr2868.; Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J. et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.; Krop I.E., Kim S.B., Martin A.G., LoRusso P.M., Ferrero J.M., BadovinacCrnjevic T. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754. https://doi.org/10.1016/S1470-2045(17)30313-3.; Modi S., Saura C., Yamshita T., Park Y.H., Kim S., Tamura K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382:610–621. https://doi.org/10.1056/NEJMoa1914510.; Murthy R.K., Loi S., Okines A., Paplomata E., Hamilton E., Hurvitz S.A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597–609. https://doi.org/10.1056/NEJMoa1914609.; Giordano S.H., Temin S., Chandarlapaty S., Crews J.R., Esteva F.J., Kirshner J.J. et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(26):2736–2740. https://doi.org/10.1200/JCO.2018.79.2697.; Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892.; Twelves C., Cortes J., Vahdat L., Olivo M., He Y., Kaufman P.A., Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–561. https://doi.org/10.1007/s10549-014-3144-y.; Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525–1531. https://doi.org/10.1093/annonc/mdw203.; Wilks S., Puhalla S., O’Shaughnessy J., Schwartzberg L., Berrak E., Song J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2- positive breast cancer. Clin Breast Cancer. 2014;14(6):405–412. https://doi.org/10.1016/j.clbc.2014.04.004.; Inoue K., Ninomiya J., Saito T., Okubo K., Nakakuma T., Yamada H. et al.; SBCCSG-36 investigators. Eribulin, trastuzumab, and pertuzumab as firstline therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):538–547. https://doi.org/10.1007/s10637-019-00755-x.; Yamashita T., Masuda N., Saji S., Araki K., Ito Y., Takano T. et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020;21(1):391. https://doi.org/10.1186/s13063-020-04341-y.; Lutrino E.S., Orlando L., Febbraro A., Giampaglia M., Zamagni C., Schiavone P. et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori. 2020;106(4):301–305. https://doi.org/10.1177/0300891619887225.; Коваленко Е.И., Артамонова Е.В., Карабина Е.В., Андреяшкина И.И., Прокофьева Е.А., Попова Н.О. и др. Эффективность комбинации эрибулина и трастузумаба при HER2-положительном диссеминированном раке молочной железы: результаты российского наблюдательного исследования. Современная онкология. 2020;22(1):29–35. https://doi.org/10.26442/18151434.2020.1.200058.; Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M. et al.; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699. https://doi.org/10.1016/S1470-2045(14)70178-0.; Mougalian S.S., Copher R., McAllister L., Radtchenko J., Wang E.C., Broscious M. et al. Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. Philadelphia (PA)AACR. Cancer Res. 2019;79(4 Suppl.):17–28. https://doi.org/10.1158/1538-7445.SABCS18-P6-17-28.; https://www.med-sovet.pro/jour/article/view/6578

الاتاحة: https://www.med-sovet.pro/jour/article/view/6578
https://doi.org/10.21518/2079-701X-2021-20-36-46

المؤلفون: T. Ustinova V., L. Bolotina V., A. Paichadze A., A. Kachmazov A., A. Fedenko A., A. Kaprin D., Т. Устинова В., Л. Болотина В., А. Пайчадзе А., А. Качмазов А., А. Феденко А., А. Каприн Д.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 130-136 ; Медицинский Совет; № 20 (2021); 130-136 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: enzalutamide, efficiacy, hormone therapy, metastatic castration-sensitive prostate cancer, metastatic castrationresistant prostate cancer, энзалутамид, эффективность, гормональная терапия, метастатический гормоночувствительный рак предстательной железы, кастрационно-рефрактерный рак предстательной железы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6590/5973; Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 г. (заболеваемость и смертность). М.: МНИОИ имени П.А. Герцена – филиал ФГБУ «НМИЦ радиологии»; 2020. 252 с.; Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–1764. https://doi.org/10.1200/jco.1996.14.6.1756.; Sweeney C.J., Monaco F.J., Jung S.H., Wasielewski M.J., Picus J., Ansari R.H. et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13(3):435–440. https://doi.org/10.1093/annonc/mdf029.; Nakabayashi M., Ling J., Xie W., Regan M.M., Oh W.K. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13(2):125–129. https://doi.org/10.1097/PPO.0b013e3180465940.; Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. https://doi.org/10.1056/NEJMoa040720.; Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N. Jr, Jones J.A., Taplin M.E. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. https://doi.org/10.1056/NEJMoa041318.; Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. https://doi.org/10.1056/NEJMoa1209096.; Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. https://doi.org/10.1056/NEJMoa1405095.; Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–197. https://doi.org/10.1056/NEJMoa1207506.; Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992. https://doi.org/10.1016/S1470-2045(12)70379-0.; Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080–1087. https://doi.org/10.1200/JCO.2017.75.3657.; James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. https://doi.org/10.1016/S0140-6736(15)01037-5.; Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgendeprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. https://doi.org/10.1016/S1470-2045(12)70560-0.; Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70(2):256–262. https://doi.org/10.1016/j.eururo.2015.11.005.; Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700. https://doi.org/10.1016/S1470-2045(19)30082-8.; James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P. et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338–351. https://doi.org/10.1056/NEJMoa1702900.; Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. https://doi.org/10.1056/NEJMoa1207506.; Hussain M., Fizazi K., Saad F., Rathenborg P., Shore N., Ferreira U. et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465–2474. https://doi.org/10.1056/NEJMoa1800536.; Armstrong A.J., Szmulewitz R.Z., Petrylak D.P., Holzbeierlein J., Villers A., Azad A. et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974–2986. https://doi.org/10.1200/JCO.19.00799.; Armstrong A.J., Iguchi T., Azad A.A., Szmulewitz R.Z., Holzbeierlein J., Villers A. et al. LBA25 – Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Ann Oncol. 2021;32(5 Suppl.): S1300–S1301. https://doi.org/10.1016/j.annonc.2021.08.2101.; Davis I.D., Martin A.J., Stockler M.R., Begbie S., Chi K.N., Chowdhury S. et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121–131. https://doi.org/10.1056/NEJMoa1903835.; Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли. 2020;10(3s2–1):556–572. https://doi.org/10.18027/2224-5057-2020- 10-3s2-33.; Fizazi K., Scher H.I., Miller K., Basch E., Sternberg C.N., Cella D. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147–1156. https://doi.org/10.1016/S1470-2045(14)70303-1.; https://www.med-sovet.pro/jour/article/view/6590

الاتاحة: https://www.med-sovet.pro/jour/article/view/6590
https://doi.org/10.21518/2079-701X-2021-20-130-136

المؤلفون: И. Королева А., Л. Болотина В., О. Гладков А., В. Горбунова А., Л. Круглова С., Л. Манзюк В., Р. Орлова В., Е. Орлова В.

المصدر: Malignant tumours; Том 11, № 3s2-2 (2021); 99-113 ; Злокачественные опухоли; Том 11, № 3s2-2 (2021); 99-113 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: поддерживающая терапия, химиотерапия, таргетная терапия, акнеподобная сыпь, зуд, сухость кожи, трещины кожи, паронихий, ладонно-подошвенный синдром, ЛПС, EGFR

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/894/642; https://www.malignanttumors.org/jour/article/view/894

الاتاحة: https://www.malignanttumors.org/jour/article/view/894
https://doi.org/10.18027/2224-5057-2021-11-3s2-42

المؤلفون: Н. Бесова С., А. Трякин А., Е. Артамонова В., Л. Болотина В., А. Калинин Е., П. Кононец В., В. Лядов К., О. Малихова А., С. Неред Н., С. Проценко А., А. Рябов Б., И. Стилиди С., М. Тер-Ованесов Д., В. Хомяков М.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 314-329 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 314-329 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: рак желудка, аденокарцинома желудка, аденокарцинома пищеводно-желудочного перехода, лекарственная терапия, химиотерапия, трастузумаб, рамуцирумаб, ЭГДС, FISH, HER2

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/869/617; https://www.malignanttumors.org/jour/article/view/869

الاتاحة: https://www.malignanttumors.org/jour/article/view/869
https://doi.org/10.18027/2224-5057-2021-11-3s2-21

المؤلفون: Л. Болотина В., Л. Владимирова Ю., Н. Деньгина В., А. Новик В., И. Романов С.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 91-106 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 91-106 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: опухоли головы и шеи, плоскоклеточный рак, рак носоглотки, рак щитовидной железы, химиотерапия, лучевая терапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/855/603; https://www.malignanttumors.org/jour/article/view/855

الاتاحة: https://www.malignanttumors.org/jour/article/view/855
https://doi.org/10.18027/2224-5057-2021-11-3s2-06

المؤلفون: М. Федянин Ю., С. Ачкасов И., Л. Болотина В., О. Гладков А., В. Глебовская В., С. Гордеев С., А. Карачун М., Н. Козлов А., Л. Любченко Н., О. Малихова А., З. Мамедли З., Б. Медведева М., О. Обухова А., А. Петров С., Д. Подлужный В., С. Проценко А., А. Рыжков Д., И. Рыков В., Д. Сидоров В., А. Трякин А., А. Цуканов С., Ю. Шелыгин А.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 330-372 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 330-372 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: рак ободочной кишки и ректосигмоидного соединения, химиотерапия, таргетная терапия, метастазэктомия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/870/618; https://www.malignanttumors.org/jour/article/view/870

الاتاحة: https://www.malignanttumors.org/jour/article/view/870
https://doi.org/10.18027/2224-5057-2021-11-3s2-22

المؤلفون: М. Федянин Ю., С. Ачкасов И., Л. Болотина В., О. Гладков А., В. Глебовская В., С. Гордеев С., А. Карачун М., Н. Козлов А., Л. Любченко Н., О. Малихова А., З. Мамедли З., Б. Медведева М., О. Обухова А., А. Петров С., Д. Подлужный В., С. Проценко А., А. Рыжков Д., И. Рыков В., Д. Сидоров В., А. Трякин А., А. Цуканов С., Ю. Шелыгин А.

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 350-391 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 350-391 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: рак ободочной кишки и ректосигмоидного соединения, химиотерапия, таргетная терапия, метастазэктомия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/771/535; https://www.malignanttumors.org/jour/article/view/771

الاتاحة: https://www.malignanttumors.org/jour/article/view/771
https://doi.org/10.18027/2224-5057-2020-10-3s2-22

المؤلفون: Л. Болотина В., Л. Владимирова Ю., Н. Деньгина В., А. Новик В., И. Романов С.

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 93-108 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 93-108 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: опухоли головы и шеи, плоскоклеточный рак, рак носоглотки, рак щитовидной железы, химиотерапия, лучевая терапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/754/519; https://www.malignanttumors.org/jour/article/view/754

الاتاحة: https://www.malignanttumors.org/jour/article/view/754
https://doi.org/10.18027/2224-5057-2020-10-3s2-06

المؤلفون: P. Nikiforovich A., P. Rumiantsev O., I. Sleptsov V., T. Ustinova V., K. Slashchuk Yu., S. Vorobyev L., S. Serzhenko S., A. Abrosimov Yu., A. Kudryavtseva V., A. Semenov A., R. Chernikov A., A. Polyakov A., A. Fedenko A., L. Bolotina V., A. Paychadze A., A. Trushin Y., A. Kaprin D., G. Zakharova S., П. Никифорович А., П. Румянцев О., И. Слепцов В., Т. Устинова В., К. Слащук Ю., С. Воробьев Л., С. Серженко С., А. Абросимов Ю., А. Кудрявцева В., А. Семенов А., Р. Черников А., А. Поляков П., А. Феденко А., Л. Болотина В., А. Пайчадзе А., А. Трушин Ю., А. Каприн Д., Г. Захарова С.

المصدر: Siberian journal of oncology; Том 19, № 5 (2020); 131-144 ; Сибирский онкологический журнал; Том 19, № 5 (2020); 131-144 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-5

مصطلحات موضوعية: anaplastic thyroid cancer, BRAFV600E mutation, targeted therapy, neoadjuvant therapy, анапластический рак щитовидной железы, таргетная терапия, неоадъювантная терапия, мутация BRAFV600E

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1588/797; Smallridge R.C., Ain K.B., Asa S.L., Bible K.C., Brierley J.D., Burman K.D., Kebebew E., Lee N.Y., Nikiforov Y.E., Rosenthal M.S., Shah M.H., Shaha A.R., Tuttle R.M.; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov; 22(11): 1104–39. doi:10.1089/thy.2012.0302.; Giuffrida D., Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000; 11(9): 1083–9. doi:10.1023/a:1008322002520.; Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011; 7(10): 569–80. doi:10.1038/ nrendo.2011.142.; Ahmed S., Ghazarian M.P., Cabanillas M.E., Zafereo M.E., Williams M.D., Vu T., Schomer D.F., Debnam J.M. Imaging of Anaplastic Thyroid Carcinoma. AJNR Am J Neuroradiol. 2018 Mar; 39(3): 547–551. doi:10.3174/ajnr.A5487.; Rao S.N., Zafereo M., Dadu R., Busaidy N.L., Hess K., Cote G.J., Williams M.D., William W.N., Sandulache V., Gross N., Gunn G.B., Lu C., Ferrarotto R., Lai S.Y., Cabanillas M.E. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 May; 27(5): 672–681. doi:10.1089/thy.2016.0395.; FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation [Internet]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenibplus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation (cited 18.08.2020).; Subbiah V., Kreitman R.J., Wainberg Z.A., Cho J.Y., Schellens J.H.M., Soria J.C., Wen P.Y., Zielinski C., Cabanillas M.E., Urbanowitz G., Mookerjee B., Wang D., Rangwala F., Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600- Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 Jan 1; 36(1): 7–13. doi:10.1200/JCO.2017.73.6785.; Пылев А.Л., Жандарова А.А., Петров К.С., Романов Д.С., Лисовой В.А., Голуб С.В. Анапластический рак щитовидной железы. Есть ли свет в конце туннеля? Опухоли головы и шеи. 2020; 10(1): 10–19.; Ciarallo A., Marcus C., Taghipour M., Subramaniam R.M. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clin. 2015 Apr; 10(2): 265–78. doi:10.1016/j.cpet.2014.12.009.; Santhanam P., Khthir R., Solnes L.B., Ladenson P.W. The relationship of braf.v600e mutation status to fdg pet/ct avidity in thyroid cancer: a review and meta-analysis. Endocr Pract. 2018; 24(1): 21–26. doi:10.4158/EP-2017-0080.; Landa I., Ibrahimpasic T., Boucai L., Sinha R., Knauf J.A., Shah R.H., Dogan S., Ricarte-Filho J.C., Krishnamoorthy G.P., Xu B., Schultz N., Berger M.F., Sander C., Taylor B.S., Ghossein R., Ganly I., Fagin J.A. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016 Mar 1; 126(3): 1052–66. doi:10.1172/JCI85271.; Quiros R.M., Ding H.G., Gattuso P., Prinz R.A., Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005; 103(11): 2261–8. doi:10.1002/cncr.21073.; Lim A.M., Taylor G.R., Fellowes A., Cameron L., Lee B., Hicks R.J., McArthur G.A., Angel C., Solomon B., Rischin D. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. J Natl Compr Canc Netw. 2016 Mar; 14(3): 249–54. doi:10.6004/jnccn.2016.0030.; Paraiso K.H., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010 Jun 8; 102(12): 1724–30. doi:10.1038/sj.bjc.6605714.; Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., Kudchadkar R., Burris H.A.3rd, Falchook G., Algazi A., Lewis K., Long G.V., Puzanov I., Lebowitz P., Singh A., Little S., Sun P., Allred A., Ouellet D., Kim K.B., Patel K., Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov 1; 367(18): 1694–703. doi:10.1056/NEJMoa1210093.; Cabanillas M.E., Ferrarotto R., Garden A.S., Ahmed S., Busaidy N.L., Dadu R., Williams M.D., Skinner H., Gunn G.B., Grosu H., Iyer P., Hofmann M.C., Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 Jul; 28(7): 945–951. doi:10.1089/thy.2018.0060.; Wang J.R., Zafereo M.E., Dadu R., Ferrarotto R., Busaidy N.L., Lu C., Ahmed S., Gule-Monroe M.K., Williams M.D., Sturgis E.M., Goepfert R.P., Gross N.D., Lai S.Y., Gunn G.B., Phan J., Rosenthal D.I., Fuller C.D., Morrison W.H., Iyer P., Cabanillas M.E. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 Aug; 29(8): 1036–43. doi:10.1089/thy.2019.0133.; Cabanillas M.E., Dadu R., Iyer P., Wanland K.B., Busaidy N.L., Ying A., Gule-Monroe M., Wang J.R., Zafereo M., Hofmann M.C. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020; 30(9): 1288–96. doi:10.1089/thy.2019.0514.; Midthun L., Shaheen S., Deisch J., Senthil M., Tsai J., Hsueh C.T. Concomitant KRAS and BRAF mutations in colorectal cancer. J Gastrointest Oncol. 2019 Jun; 10(3): 577–581. doi:10.21037/jgo.2019.01.10.; Abravanel D.L., Nishino M., Sholl L.M., Ambrogio C., Awad M.M. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. J Thorac Oncol. 2018 Aug; 13(8): e131e133. doi:10.1016/j.jtho.2018.03.026.; Bunney P.E., Zink A.N., Holm A.A., Billington C.J., Kotz C.M. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet. Physiol Behav. 2017 Jul 1; 176: 139–48. doi:10.1016/j.physbeh.2017.03.040.; Bastman J.J., Serracino H.S., Zhu Y., Koenig M.R., Mateescu V., Sams S.B., French J.D. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2016; 101(7): 2863–2873. doi:10.1210/jc.2015-4227.; Naing A., Gainor J.F., Gelderblom H., Forde P.M., Butler M.O., Lin C.C., Sharma S., Ochoa de Olza M., Varga A., Taylor M., Schellens J.H.M., Wu H., Sun H., Silva A.P., Faris J., Mataraza J., Cameron S., Bauer T.M. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020 Mar; 8(1): e000530. doi:10.1136/jitc-2020-000530.; Capdevila J., Wirth L.J., Ernst T., Ponce Aix S., Lin C.C., Ramlau R., Butler M.O., Delord J.P., Gelderblom H., Ascierto P.A., Fasolo A., Führer D., Hütter-Krönke M.L., Forde P.M., Wrona A., Santoro A., Sadow P.M., Szpakowski S., Wu H., Bostel G., Faris J., Cameron S, Varga A., Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10; 38(23): 2620–2627. doi:10.1200/JCO.19.02727.; https://www.siboncoj.ru/jour/article/view/1588

الاتاحة: https://www.siboncoj.ru/jour/article/view/1588
https://doi.org/10.21294/1814-4861-2020-19-5-131-144

المؤلفون: L. Moskvicheva I., L. Bolotina V., Л. Москвичева И., Л. Болотина В.

المصدر: Research and Practical Medicine Journal; Том 7, № 4 (2020); 118-134 ; Research'n Practical Medicine Journal; Том 7, № 4 (2020); 118-134 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2020-7-4

مصطلحات موضوعية: locally advanced and metastatic pancreatic cancer, adenocarcinoma, palliative cancer care, chemotherapy, drug therapy, oncology, местно-распространенный и метастатический рак поджелудочной железы, протоковая аденокарцинома, паллиативная онкологическая помощь, химиотерапия, лекарственная терапия, онкология

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/637/396; McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21;24(43):4846–4861. https://doi.org/10.3748/wjg.v24.i43.4846; Состояние онкологической помощи населению России в 2018 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019, 236 с.; Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013 Sep;63(5):318–348. https://doi.org/10.3322/caac.21190; Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017 Dec;6(6):58. https://doi.org/10.21037/cco.2017.12.04; Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019 Aug 8;14(1):141. https://doi.org/10.1186/s13014-019-1345-6; Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci. 2019 Sep 13;20(18):4543. https://doi.org/10.3390/ijms20184543; Милешина С.Е. Противоопухолевые средства. Доступно по: http://do.rsmu.ru/fileadmin/user_upload/pf/protivoopukholevye_sr-va.pdf Дата обращения: 21.06.2020.; Покатаев И.А., Алиева С.Б., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Патютко Ю.И. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2019;3s2(9):456–468. https://doi.org/10.18027/2224-5057-2019-9-3s2-456-468; Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403; Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017 Jun 22;18(7):E1338. https://doi.org/10.3390/ijms18071338; Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640–1648. https://doi.org/10.1200/JCO.2012.43.3680; Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212–2217. https://doi.org/10.1200/JCO.2006.09.0886; Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513–5518. https://doi.org/10.1200/JCO.2009.24.2446; Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, et al. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore). 2017 Jan;96(1):e5702. https://doi.org/10.1097/MD.0000000000005702; Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946–3952. https://doi.org/10.1200/JCO.2005.05.1490; Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778–3785. https://doi.org/10.1200/JCO.2008.20.9007; Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15;22(18):3776–3783. https://doi.org/10.1200/JCO.2004.12.082; Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CAL-GB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617–3622. https://doi.org/10.1200/JCO.2010.28.1386; Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960–1966. https://doi.org/10.1200/JCO.2006.07.9525; Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817– 1825. https://doi.org/10.1056/NEJMoa1011923; Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801–810. https://doi.org/10.1016/S1470-2045(16)00172-8; JG, de Jesus VHF, Camandaroba MPG, Dettino ALA. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Ther Adv Med Oncol. 2019;11:1-13. https://doi.org/10.1177/1758835919874650; Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23–29. https://doi.org/10.1200/JCO.2012.44.4869; Wang Z-Q, Zhang F, Deng T, Zhang L, Feng F, Wang F-H, et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond). 2019 08;39(1):26. https://doi.org/10.1186/s40880-019-0367-7; Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018 Nov 15;10(11):421– 430. https://doi.org/10.4251/wjgo.v10.i11.421; Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369; Tsujimoto A, Sudo K, Nakamura K, Kita E, Hara R, Takayama W, et al. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci Rep. 2019 07;9(1):16187. https://doi.org/10.1038/s41598-019-52486-x; Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, et al. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol. 2019 Oct;10(5):910–917. https://doi.org/10.21037/jgo.2019.06.02; Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer. 2019;10(18):4420–4429. https://doi.org/10.7150/jca.29898; Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, et al. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 Aug;9(15):5406–5415. https://doi.org/10.1002/cam4.3229; Charton E, Bachet J-B, Hammel P, Desramé J, Chibaudel B, Cohen R, et al. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Med. 2019 Sep;8(11):5079–5088. https://doi.org/10.1002/cam4.2311; Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol. 2018 Aug;144(8):1503–1507. https://doi.org/10.1007/s00432-018-2666-9; Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014 Sep 9;111(6):1132–1138. https://doi.org/10.1038/bjc.2014.418; Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 25;381(4):317– 327. https://doi.org/10.1056/NEJMoa1903387; Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681. https://doi.org/10.1016/j.ejca.2011.04.011; Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545– 557. https://doi.org/10.1016/S0140-6736(15)00986-1; Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423–2429. https://doi.org/10.1200/JCO.2013.53.6995; Lee MG, Lee SH, Lee SJ, Lee YS, Hwang J-H, Ryu JK, et al. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy. 2013;59(4):273–279. https://doi.org/10.1159/000356158; Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80(5–6):301–306. https://doi.org/10.1159/000329803; Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol. 2019 Nov 15;11(11):1021–1030. https://doi.org/10.4251/wjgo.v11.i11.1021; Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009 Jan;63(2):313–319. https://doi.org/10.1007/s00280-008-0741-7; Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011 Feb;67(2):249–254. https://doi.org/10.1007/s00280-010-1311-3; Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang H-M, et al. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat. 2020 Jan;52(1):254–262. https://doi.org/10.4143/crt.2019.190; Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, et al. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers (Basel). 2020 Apr 30;12(5):1131. https://doi.org/10.3390/cancers12051131; Chae H, Jeong H, Cheon J, Chon HJ, Ryu H, Kim I-H, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020;12:1–8. https://doi.org/10.1177/1758835920923424; de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol. 2020;12: 1–13. https://doi.org/10.1177/1758835920905408; Buwenge M, Macchia G, Arcelli A, Frakulli R, Fuccio L, Guerri S, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. J Pain Res. 2018;11:2169–2178. https://doi.org/10.2147/JPR.S167994; Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324; Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S; Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317–326. https://doi.org/10.1016/S1470-2045(13)70021-4; Wang C, Liu X, Wang X, Wang Y, Cha N. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Sep;97(36):e12260. https://doi.org/10.1097/MD.0000000000012260; Хитрова А.Н., Болотина Л.В., Корниецкая А.Л., Москвичева Л.И. Проведение высокоинтенсивной фокусированной ультразвуковой терапии в рамках комбинированного лечения неоперабельной больной раком поджелудочной железы. Онкология. Журнал им. П.А.Герцена. 2020;9(1):50– 54. https://doi.org/10.17116/onkolog2020901150; Neuzillet C, Gaujoux S, Williet N, Bachet J-B, Bauguion L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis. 2018;50(12):1257–1271. https://doi.org/10.1016/j.dld.2018.08.008; Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem J-L, Malka D, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;11:1–43. https://doi.org/10.1177/1758835919875568; https://www.rpmj.ru/rpmj/article/view/637

الاتاحة: https://www.rpmj.ru/rpmj/article/view/637
https://doi.org/10.17709/2409-2231-2020-7-4-10

المؤلفون: L. Bolotina V., I. Zaborskiy N., K. Safiullin N., E. Gurin V., L. Volodina N., E. Semyonova S., A. Gurchev A., O. Gladkikh P., A. Zhabina S., A. Tarasova V., Л. Болотина В., И. Заборский Н., К. Сафиуллин Н., Э. Гурин В., Л. Володина Н., Е. Семёнова С., А. Гурчев А., О. Гладких П., А. Жабина С., А. Тарасова В.

المصدر: Cancer Urology; Том 16, № 3 (2020); 135-142 ; Онкоурология; Том 16, № 3 (2020); 135-142 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: urothelial cancer, vinflunine, efficacy, safety, уротелиальный рак, винфлунин, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1368/1198; Witjes J.A., Comperat E., Cowan N.C. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65 (4):778-92. DOI:10.1016/j.eururo.2013.11.046.; Williams S.B., Shan Y., Ray-Zack M.D. et al. Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer. JAMA Surg 2019;154(8):e191629. DOI:10.1001/jamasurg.2019.1629.; Winquist E., Kirchner T.S., Segal R. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171(2 Pt 1):561-9. DOI:10.1097/01.ju.0000090967.08622.33.; Apolo A.B., Vogelzang N.J., Theodorescu D. New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol Educ Book 2015;35:105-12. DOI:10.14694/EdBook_AM.2015.35.105.; Korkes F., Palou J. High mortality rates after radical cystectomy: we must have acceptable protocols and consider the rationale of cutaneous ureterostomy for high-risk patients. Int Braz J Urol 2019;45(6):1090-3. DOI:10.1590/S1677-5538.IBJU.2019.05.03.; Klapheke A., Yap S.A., Pan K., Cress R.D. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol 2018;36 (6):308.e19-25. DOI:10.1016/j.urolonc.2018.03.008.; DelFattore J. Death by Stereotype? Cancer treatment in unmarried patients. N Engl J Med 2019; 381(10):982-5. DOI:10.1056/NEJMms1902657.; Merck KGaA. US FDA breakthrough therapy designation and submission of application for Bavencio for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma. [Press release] April 9, 2020.; Kapetanakis V., Prawitz T., Schlichting M. et al. Comparing progression-free survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods. J Clin Oncol 2020;38(Suppl 6):573.; Baldini C., Champiat S., Vuagnat P., Massard C. Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. Onco Targets Ther 2019;12:2505-12. DOI:10.2147/OTT.S141040.; Teo M.Y., Seier K., Ostrovnaya I. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 2018;36(17):1685-94. DOI:10.1200/JCO.2017.75.7740.; Powles T., Duran I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748-57. DOI:10.1016/S0140-6736(17)33297-X.; Rosenberg J.E., O'Donnell P.H., Balar A.V. et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37(29):2592-600. DOI:10.1200/JCO.19.01140.; Loriot Y., Necchi A., Park S. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338-48. DOI:10.1056/NEJMoa1817323.; Powles T. 2020 American Society of Clinical Oncology annual meeting: Abstract LBA1. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Available at: https://meeting-library.asco.org/record/186872/slide.; Волкова М.И., Черняев В.А., Матвеев В.Б. и др. Винфлунин во 2-й линии терапии у больных распространенным переходно-клеточным раком мочевыводящих путей в клинической практике: результаты наблюдательного исследования. Онкоурология 2017;13(3):110-8. DOI:10.17650/1726-9776-2017-13-3110-118.; Van Persijn van Meerten E.L., Gelderblom H., Bloem J.L. RECIST revised: implications for the radiologist. A review article on the modi ed RECIST guideline. Eur Radiol 2010;20 (6):1456-67. DOI:10.1007/s00330-009-1685-y.; Bellmunt J., Theodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454-61. DOI:10.1200/JCO.2008.20.5534.; Medioni J., Di Palma M., Guillot A. et al. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer 2016;16(1):217. DOI:10.1186/s12885-016-2262-9.; Pistamaltzian N., Tzannis K., Pissanidou V. et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs 2016;27(1):48-53. DOI:10.1097/CAD.0000000000000297.; Holmsten K., Dohn L., Jensen N.V. et al. Vinflunine treatment in patients with metastatic urothelial cancer: a Nordic retrospective multicenter analysis. Oncol Lett 2016;12(2):1293-300. DOI:10.3892/ol.2016.4775.; Hussain S.A. ESMO 2016:abstract #800P and poster.; Passalacqua R. ASCO 2016: abstract #e16031.; Castellano D., Puente J., de Velasco G. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014;14:779. DOI:10.1186/1471-2407-14-779.; Culine S., Theodore C., De Santis M. et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94(10):1395-401. DOI:10.1038/sj.bjc.6603118.; Vaughn D.J., Srinivas S., Stadler W.M. et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009;115 (18):4110-7. DOI:10.1002/cncr.24460.; Retz M., de Geeter P., Goebell P.J. et al. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer 2015;15:455. DOI:10.1186/s12885-015-1434-3.; https://oncourology.abvpress.ru/oncur/article/view/1368

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1368
https://doi.org/10.17650/1726-9776-2020-16-3-135-142

المؤلفون: T. Ustinova V., L. Bolotina V., A. Fedenko A., H. Gevorgyan S., A. Paichadze A., A. Kornietskaya L., N. Vorobyev V., K. Nushko M., A. Kalpinskiy S., A. Kachmazov A., K. Isaeva M., Т. Устинова В., Л. Болотина В., А. Феденко А., Г. Геворгян С., А. Пайчадзе А., А. Корниецкая Л., Н. Воробьев В., К. Нюшко М., А. Калпинский С., А. Качмазов А., К. Исаева М.

المساهمون: No funding of this work has been held., Финансирование данной работы не проводилось.

المصدر: Research and Practical Medicine Journal; Том 6, № 3 (2019); 129-137 ; Исследования и практика в медицине; Том 6, № 3 (2019); 129-137 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2019-6-3

مصطلحات موضوعية: testicular cancer, neoadjuvant chemotherapy, orchifuniculectomy, testicular germ cell tumors, neseminoma, therapeutic pathomorphosis, рак яичка, неоадъювантная химиотерапия, орхфуникулэктомия, герминогенные опухоли яичка, несеминома, лечебный патоморфоз

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/429/319; Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Prev. 2010 May;19 (5):1151–9. DOI:10.1158/1055–9965.EPI-10–0031; Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D’Aniello C, et al. Testicular cancer from diagnosis to epigenetic factors. Oncotarget. 2017 Sep 18;8 (61):104654–104663. DOI:10.18632/oncotarget.20992; Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018, 250 с. Доступно по: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf; Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007 Sep;8 (9):784–96. DOI:10.1016/S1470–2045 (07)70246–2; Masters J, Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer. 2003 Jul;3 (7):517–25. DOI:10.1038/nrc1120; Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K, Smart CJ. Orchiectomy aſter chemotherapy in рatients with metastatic testicular cancer. Is it indicated? Cancer. 1995 Feb 15;75 (4):1018–24. DOI:10.1002/1097–0142 (19950215)75:43.0.co;2-y; Ondrus D, Hornák M, Breza J, Mat’oska J, Schnorrer M, Belan V, Kausitz J. Delayed orchiectomy aſter chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol. 2001;32 (4):665–7.; Geldart TR, Simmonds PD, Mead GM. Orchidectomy aſter chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int. 2002 Sep;90 (4):451–5.; Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW. Histological Outcome of Delayed Orchidectomy aſter Primary Chemotherapy for Metastatic Germ Cell Tumour of the Testis. Clin Oncol (R Coll Radiol). 2008 Apr;20 (3):247–52. DOI:10.1016/j.clon.2007.11.009; Трякин А. А., Федянин М. Ю., Буланов А. А., Матвеев В. Б., Сергеев Ю. С., Файнштейн И. А., и др. Лечение больных несеминомными герминогенными опухолями неблагоприятной прогностической группы с большой распространенностью опухолевого процесса. Злокачественные опухоли. 2017;7 (3):23–30. DOI:10.18027/2224–5057–2017–7–3–23–29; https://www.rpmj.ru/rpmj/article/view/429

الاتاحة: https://www.rpmj.ru/rpmj/article/view/429
https://doi.org/10.17709/2409-2231-2019-6-3-12

المؤلفون: L. Bolotina V., C. Kravtsov A., T. Ustinova V., E. Karpenko Yu., A. Kornietskaya L., A. Paichadze A., V. Galkin N., A. Kaprin D., A. Fedenko A., Л. Болотина В., С. Кравцов А., Т. Устинова В., Е. Карпенко Ю., А. Корниецкая Л., А. Пайчадзе А., В. Галкин Н., А. Каприн Д., А. Феденко А.

المساهمون: No funding of this work has been held., Финансирование данной работы не проводилось.

المصدر: Research and Practical Medicine Journal; Том 6, № 3 (2019); 115-128 ; Исследования и практика в медицине; Том 6, № 3 (2019); 115-128 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2019-6-3

مصطلحات موضوعية: squamous cell carcinoma of the head and neck, platinum-containing chemotherapy, immuno-oncological drugs, 2-line drug therapy, expression of PD-L1, плоскоклеточный рак головы и шеи, платиносодержащая химиотерапия, иммуноонкологические препараты, лекарственная терапия 2-й линии, экспрессия PD-L1

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/428/318; Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359 (11):1116–27. DOI:10.1056/NEJMoa0802656; Болотина Л. В., Владимирова Л. Ю., Деньгина Н. В., Новик А. В., Романов И. С. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли. 2017;7 (3 S2):66–76. DOI:10.18027/2224–5057–20l7–7-3s2–66–76; Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep. 1985 Jun;69 (6):577–81.; Williams SD, Velez-Garcia E, Essessee I, Ratkin G, Birch R, Einhorn LH. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer. 1986 Jan 1;57 (1):18–23. DOI:10.1002/1097–0142 (19860101)57:13.0.co;2-v; Forastiere A, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. A Southwest Oncology Group Study. J Clin Oncol. 1992 Aug;10 (8):1245–51. DOI:10.1200/JCO.1992.10.8.1245; Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or aſter platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16 (5):583–94. DOI:10.1016/S1470–2045 (15)70124–5.; Franceschi S, Munoz N, BoschXF, Snijders PJ, WalboomersJM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev. 1996 Jul;5 (7):567–75.; Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Apr;22 (2):128–42. DOI:10.1016/j.semradonc.2011.12.004.; Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002 Dec;12 (6):431–41.; Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, et al: Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May;56:1–7. DOI:10.1016/j.oraloncology.2016.02.011; Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, et al. Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity. Cancer. 2016 Dec 1;122 (23):3624–3631. DOI:10.1002/cncr.30227; Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011 Nov 2;306 (17):1891–901. DOI:10.1001/jama.2011.1592.; Deeb R, Sharma S, Mahan M, Al-Khudari S, Hall F, Yoshida A, Schweitzer V. Head and neck cancer in transplant recipients. Laryngoscope. 2012 Jul;122 (7):1566–9. DOI:10.1002/lary.23328; Kruse ALD, Gratz KW. Oral carcinoma aſter hematopoietic stem cell transplantation — a new classification based on a literature review over 30 years. Head Neck Oncol. 2009 Jul 22;1:29. DOI:10.1186/1758–3284–1-29.; Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G. Distribution of immune cells in head and neck cancer: CD8+ T cells and CD20+ B cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer. 2009 Aug 22;9:292. DOI:10.1186/1471–2407–9-292; Cho Y-A, Yoon H-J, Lee J-I, Hong S-P, Hong S-D. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011 Dec;47 (12):1148–53. DOI:10.1016/j.oraloncology.2011.08.007; Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013 Jan 1;73 (1):128–38. DOI:10.1158/0008– 5472.CAN-12–2606.; Ukpo OC, Thorstad WL, Lewis JS. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013 Jun;7 (2):113–21. DOI:10.1007/s12105–012–0406-z.; ASCO 2017: Abstracts Head and Neck Pai et al. #6040; Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366 (26):2443–54. DOI:10.1056/NEJMoa1200690.; Seiwert T, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. J Clin Oncol. 2014;32 (5S) (suppl; abstr 6011).; Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti- PD-L1 antibody. J Clin Oncol. 2014;32 (5s) (suppl; abstr 3002).; Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375 (19):1856– 1867. DOI:10.1056/NEJMoa1602252; Robert L, Ferris et al. Presented at ASTRO, Feb 2017, abstract LBA10.; Cohen EE, et al. ESMO 2017 (Abstract LBA45).; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers. Version 2.2018.; Ribas A, et al. Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? Clin Cancer Res. 2009 Dec 1;15 (23):7116–8. DOI:10.1158/1078–0432.CCR-09–2376.; Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15 (23):7412–20. DOI:10.1158/1078–0432.CCR-09– 1624; Lynch T, et al. Overall survival and progression free survival results for a randomized phase 2 trial of Ipilimumab and Paclitaxel/Carboplatin in first-line stage IIIB/IV NSCLC. Presented at: ESMO, 2010; poster 375PD.; Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019; 37 (suppl; abstr 6000).; https://www.rpmj.ru/rpmj/article/view/428

الاتاحة: https://www.rpmj.ru/rpmj/article/view/428
https://doi.org/10.17709/2409-2231-2019-6-3-11

المؤلفون: T. Ustinova V., K. Nyushko M., L. Bolotina V., N. Kharchenko V., A. Paychadze A., I. Taraki A., B. Alekseev Ya., A. Krasheninnikov A., A. Kaprin D., Т. Устинова В., К. Нюшко М., Л. Болотина В., Н. Харченко В., А. Пайчадзе А., И. Тараки А., Б. Алексеев Я., А. Крашенинников А., А. Каприн Д.

المصدر: Cancer Urology; Том 14, № 3 (2018); 58-67 ; Онкоурология; Том 14, № 3 (2018); 58-67 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-3

مصطلحات موضوعية: prostate cancer, neoadjuvant chemohormonal therapy, adjuvant chemohormonal therapy, рак предстательной железы, неоадъювантная химиогормональная терапия, адъювантная химиогормональная терапия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/862/786; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/609; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/610; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/611; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/612; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/613; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/862/614; Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Chi K.N., Chin J.L., Winquist E. et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180(2):565–70. DOI:10.1016/j.juro.2008.04.012. PMID: 18554663.; Clark P.E., Peereboom D.M., Dreicer R. et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001;57(2):281–5. PMID: 11182337.; Dreicer R., Magi-Galluzzi C., Zhou M. et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138–42. DOI:10.1016/j.urology.2004.01.040. PMID: 15183967.; Friedman J., Dunn R.L., Wood D. et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179(3):911–6. DOI:10.1016/j.juro.2007.10.064. PMID: 18207190.; Garzotto M., Higano C.S., O’Brien C. et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010;116(7):1699–708. DOI:10.1002/cncr.24960. PMID: 20143429.; Konety B.R., Eastham J.A., Reuter V.E. et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004;171(2):709–13. DOI:10.1097/01.ju.0000108122.36893.5a. PMID: 14713792. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022534705625621.; Mellado B., Font A., Alcaraz A. et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009;101(8):1248–52. DOI:10.1038/sj.bjc.6605320. PMID: 19755998. Available at: http:// dx.doi.org/10.1038/sj.bjc.6605320.; Narita S., Tsuchiya N., Kumazawa T. et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 2012;10:2–7. DOI:10.1186/1477-7819-10-1. PMID: 22214417.; Zurita A.J., Pisters L.L., Wang X. et al. HHS Public Access. 2016;18(3): 276–80.; Prayer-galetti T., Sacco E., Pagano F. et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007;100(2):274–80. DOI:10.1111/j.1464-410X.2007.06760.x. PMID: 17355369.; Sella A., Zisman A., Kovel S. et al. Neoadjuvant chemohormonal therapy in poorprognosis localized prostate cancer. Urology 2008;71(2):323–7. DOI:10.1016/j.urology.2007.08.060. PMID: 18308112.; Shepard D.R., Dreicer R., Garcia J. et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009;181(4):1672–7. DOI:10.1016/j.juro.2008.11.121. PMID: 19230915. Available at: http:// dx.doi.org/10.1016/j.juro.2008.11.121.; Womble P.R., Vanveldhuizen P.J., Nisbet A.A. et al. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011;186(3):882–7. DOI:10.1016/j.juro.2011.04.087. PMID: 21791342. Available at: http:// dx.doi.org/10.1016/j.juro.2011.04.087.; Epstein J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149(6):1478–81. PMID: 8501792.; Nelson B.A., Shappell S.B., Chang S.S. et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2006;97(6):1169–72. DOI:10.1111/j.1464-410X.2006.06148.x. PMID: 16686706.; Stamey T.A. Biological determinants of cancer progression in men with prostate cancer. Jama 1999;281(15):1395. PMID: 10217055. Available at: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.281.15.1395.; Pettaway C.A., Pisters L.L., Troncoso P. et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18(5):1050–7. PMID: 10694556. DOI:10.1200/JCO.2000.18.5.1050.; Eastham J.A., Kelly W.K., Grossfeld G.D. et al. Cancer and leukemia group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;55–62. PMID: 14747042.; Fizazi K., Faivre L., Lesaunier F. et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015;16(7):787–94. DOI:10.1016/S1470-2045(15)00011-X. PMID: 26028518.; Ahlgren G.M., Flodgren P., Tammela T.L.J. et al. Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 scandinavian prostate cancer group 12 trial. Eur Urol 2018;73(6):870–6. DOI:10.1016/j.eururo.2018.01.012. PMID: 29395502.; https://oncourology.abvpress.ru/oncur/article/view/862

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/862
https://doi.org/10.17650/1726-9776-2018-14-3-58-67

المؤلفون: Б. Алексеев Я., В. Борисов И., В. Бяхов И., Е. Велиев И., Л. Владимирова Ю., Л. Болотина В., М. Волкова И., К. Гафанов Р., А. Зырянов В., П. Карлов А., В. Матвеев Б., В. Моисеенко М., Д. Носов А., К. Нюшко М., И. Русаков Г., В. Шерстнев М.

المصدر: Cancer Urology; Том 13, № 1 (2017); 157-160 ; Онкоурология; Том 13, № 1 (2017); 157-160 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-1

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/671/636; Носов Д.А., Воробьев Н.А., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. С. 343–352. Доступно по: http://www.rosoncoweb.ru/standarts/ RUSSCO/29.pdf. [Nosov D.A., Vorob’ev N.A., Gladkov O.A. et al. Practical guidelines for prostate cancer drug therapy. Pp. 343–352. Available at: http://www.rosoncoweb.ru/standarts/RUSSCO/29.pdf. (In Russ.)]. DOI:10.18027/2224-5057-2016-4s2-343-352.; Российские клинические рекомендации по урологии по лечению мКРРПЖ. Джевтана. М., 2013. 304 с. Доступно по: http:// www.minzdravrb.ru/minzdrav/docs/urol.pdf. [Russian clinical urological guidelines for mCRPC treatment. Dzhevtana. Moscow, 2013. 304 p. Available at: http://www.minzdravrb.ru/ minzdrav/docs/urol.pdf. (In Russ.)].; Mottet N., Bellmunt J., Briers E. et al. Guidelines on prostate cancer. Eur Associat Urol 2016. URL: http://uroweb.org/guideline/prostate-cancer.; NCCN Guidelines. Version 1.2017.; Parker C., Gillessen S., Heidenreich A. et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(suppl 5): 69–77. DOI:10.1093/annonc/mdv222. PMID: 26205393.; Sweeney C., Chen Y.-H., Carducci M.A. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Proc Am Soc Clin Oncol 2014;32(suppl 1): BA2 (abstr).; James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163–77. DOI:10.1016/S0140-6736(15)01037-5. PMID: 26719232.; van Soest R.J., de Wit R. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials. BMC Med 2015;13:304. DOI:10.1186/s12916-015-0543-9. PMID: 26695172.; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI:10.1056/NEJMoa040720. PMID: 15470213.; Berthold D.R., Pond G.R., Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242–5. DOI:10.1200/JCO.2007.12.4008. PMID: 18182665.; Berthold D.R., Pond G.R., Roessner M. et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14(9):2763–7. DOI:10.1158/1078-0432.CCR-07-0944. PMID: 18451243.; Van Soest R.J., de Morree E.S., Shen L. et al. Initial biopsy gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol 2013;66:330–6.; Oudard S., Kramer G., Caffo O. et al. Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer. BJU Int 2015;115(5):744–52. DOI:10.1111/bju.12845. PMID: 24947139.; de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI:10.1016/S0140-6736(10)61389-X. PMID: 20888992.; Bahl A., Oudard S., Tombal B. et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24(9): 2402–8. DOI:10.1093/annonc/mdt194. PMID: 23723295.; Sonpavde G., Bhor M., Hennessy D. et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer 2015;13(4):309–18. DOI:10.1016/j.clgc.2014.12.019. PMID: 25743206.; Maines F. Caffo O., Veccia A. et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 2015;96(3):498–506. DOI:10.1016/j.critrevonc.2015.07.013. PMID: 26318091.; Angelergues A. Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: the multinational, retrospective, observational CAT study. Poster 744P. Ann Oncol 2016;27(suppl 6):vi254.; Sartor A.O. TAXYNERGY: randomized phase II trial of early switch from first-line docetaxel to cabazitaxel or vice versa with CTC biomarkers in patients with mCRPC who have not received prior chemotherapy. J Clin Oncol 2016;34(suppl; abstr 5007).; Sartor A.O. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): a three-arm phase III study (FIRSTANA). J Clin Oncol 2016;34(suppl; abstr 5006).; de Bono J.S. Phase III Non-Inferiority study of cabazitaxel 20 mg/m2 versus cabazitaxel 25 mg/m2 in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (PROSELICA) J Clin Oncol 2016;34(suppl; abstr 5008). Oral presentation.; https://oncourology.abvpress.ru/oncur/article/view/671; undefined

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/671

المؤلفون: E. Artamonova V., L. Bolotina V., V. Gorbunova A., I. Demidova A., N. Zhukov V., L. Zhukova G., L. Manzyuk V., T. Semiglazova Y., Е. Артамонова В., Л. Болотина В., В. Горбунова А., И. Демидова А., Н. Жуков В., Л. Жукова Г., Л. Манзюк В., Т. Семиглазова Ю.

المصدر: Malignant tumours; № 2 (2017); 100-104 ; Злокачественные опухоли; № 2 (2017); 100-104 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: iadvanced breast cancer, eribulin, диссеминированный рак молочной железы, эрибулин

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/350/317; Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instruktsiya po meditsinskomu primeneniyu preparata Halaven® (RU LP-001782 ot 28.07.2012, s izmeneniyami ot 08.02.2017). (In Russ.)].; Towle M. J., Salvato K.A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2, pp. 496–505.; Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105, No. 10, pp. 1334–1342.; Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, No. 11, pp. 1212–1218.; Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.; Ozawa Y., Okamoto K., Adachi Y. et al. Suppression of Metastasis and Improvement of Drug Distribution by Eribulin Mesylate, EORTC-NCI-AACR, Barcelona, 2014, Vol. 5, p. 17.; Goto V., Kashiwagi S., Asano Y. et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer, AACR, 2016 [Abstr. #5127].; Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study, Lancet 2011, Vol. 377, No. 9769, pp. 914–923.; Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan, J. Clin. Oncol., 2015, Vol. 33, No. 6, pp. 594–601.; Pivot X., Marme F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.; Twelves C. et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an openlabel, phase 2 dose-confirmation study. Presented at SABCS 2014, Abstract #P3-13-04.; Wilks S., Puhalla S., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.; Araki K. et al. Eribulin Should be a Candidate Strategy in Combination with Pertuzumab Plus Trastuzumab for Taxane Pretreated HER2-Positive Advance Breast Cancer, SABCS, 2016 [Abstr. P5-15-11].; Hardy-Bessard A., Brocard F., Leheurteur M. et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic HER2-negative breast cancer (MBC): a GINECO group study, ESMO, 2016 [Abstr. #3730].; Tolaney S., Savulsky C., Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer, SABCS, 2016 [Abstr. P5-15-02].; https://www.malignanttumors.org/jour/article/view/350

الاتاحة: https://www.malignanttumors.org/jour/article/view/350
https://doi.org/10.18027/2224-5057-2017-2-100-104

المؤلفون: L. Manzyuk V., E. Kovalenko I., V. Gorbunova A., L. Bolotina V., T. Semiglazova Y., L. Zhilyaeva A., Y. Mishina A., D. Ponomarenko M., V. Goldberg E., N. Popova O., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., S. Safina Z., M. Shaidorov V., L. Vladimirova Y., I. Mitashok S., E. Prokofieva P., I. Evstigneeva V., I. Andreyashkina I., N. Abramova A., I. Popova L., A. Teterich A., E Gaisina A., V. Chubenko A., S. Limareva V., N. Tikhanovskaya M., A. Storozhakova E., N. Samaneva Y., Y. Svetitskaya V., T. Snezhko A., E. Kalabanova A., A. Povyshev Y., I. Yudina V., L. Vorotilina V., T. Andreeva V., G. Tumanyan C., A. Kozyakov E., L. Gilmutdinova A., Л. Манзюк В., Е. Коваленко И., В. Горбунова А., Л. Болотина В., Т. Семиглазова Ю., Л. Жиляева А., Ю. Мишина А., Д. Пономаренко М., В. Гольдберг Е., Н. Попова О., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., С. Сафина З., М. Шайдоров В., Л. Владимирова Ю., И. Миташок С., Е. Прокофьева П., И. Евстигнеева В., И. Андреяшкина И., Н. Абрамова А., И. Попова Л., А. Тетерич А., Е. Гайсина А., В. Чубенко А., С. Лимарева В., Н. Тихановская М., А. Сторожакова Э., Н. Саманева Ю., Я. Светицкая В., Т. Снежко А., Е. Калабанова А., А. Повышев Ю., И. Юдина В., Л. Воротилина В., Т. Андреева В., Г. Туманян С., А. Козяков Е., Л. Гильмутдинова А.

المصدر: Malignant tumours; № 3 (2017); 46-56 ; Злокачественные опухоли; № 3 (2017); 46-56 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: metastatic breast cancer, chemotherapy, eribulin, метастатический рак молочной железы, химиотерапия, эрибулин

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/391/337; Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2012, Vol. 23, pp. vii11–vii19.; Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 2011, Vol. 377, pp. 914–923.; Kaufman P. A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J. Clin. Oncol., 2015, Vol. 33, pp. 594–601.; Twelves C., Awada A., Cortes J., Yelle I., Velikova G., Olivo M., Song J., Dutcus C., Kaufman P. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer, Breast Cancer: Basic and Clinical Research, 2016, Vol. 10, pp 77–84.; Twelves C., Cortes J., Vandat L. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat., 2014, Vol. 148, pp. 553–561.; Pivot X., Marm F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.; Wilks Sh., Puhalla Sh., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.; Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instructions for the medical use of the drug Halaven® (RU LP-001782 dated 28.07.2012, as amended on 08.02.2017) (In Russ.)]; Blum J. L., Twelves C. J., Dutcus C. et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010, San Antonio, TX, USA, P6-13–01.; Towle M. J., Salvato K. A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2. pp. 496–505.; Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105. No. 10. pp. 1334–1342.; Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, pp. 1212–1218.; Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.; https://www.malignanttumors.org/jour/article/view/391

الاتاحة: https://www.malignanttumors.org/jour/article/view/391
https://doi.org/10.18027/2224-5057-2017-3-46-56